Skip to NavigationSkip to content

Vizimpro

NICE recommends Pfizer's Vizimpro, rejects AstraZeneca's Tagrisso, in non-small cell lung cancer

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a U-turn on its previous decision to reject the drug for being an ineffective use of NHS resources.

The recommendation, made after the manufacturer agreed to a confidential discount, will make the drug available on the health service specifically in locally advanced or metastatic NSCLC, that has tested positive for the epidermal growth factor receptor (EGFR) mutation.

European approval for Pfizer's Vizimpro in first-line non-small cell lung cancer

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a first-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

Data derived from a Phase 3 study examining the drugs’ use in 227 patients with EGFR-mutated metastatic NSCLC showed a “statistically significant improvement” in progression-free survival, as determined by Independent Radiologic Central (IRC) review, meeting the primary endpoint.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches